Targeting Igf-1/2 With Xentuzumab (Xe) Plus Enzalutamide (En) In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Progression On Docetaxel Chemotherapy (Dct) And Abiraterone (Abi): Randomized Phase Ii Trial Results.
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要